An amino acid-based peritoneal dialysis fluid buffered with bicarbonate versus glucose/bicarbonate and glucose/lactate solutions: An intraindividual randomized study

Peritoneal Dialysis International

Volumn 19, Issue 5, 1999, Pages 418-428

  Plum, Jörg ^a   Erren, Christine ^a   Fieseler, Claus ^a   Kirchgessner, Judith ^b   Passlick Deetjen, Jutta ^b   Grabensee, Bernd ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b FRESENIUS MEDICAL CARE   (Germany)

Author keywords

Amino acids; Bicarbonate; Clearance; Metabolic changes; Peritoneal dialysis solutions

Indexed keywords

AMINO ACID; BICARBONATE; BUFFER; CARBONIC ACID; CREATININE; GLUCOSE; INSULIN; LACTIC ACID; NITROGEN; OSMOTIC AGENT; PERITONEAL DIALYSIS FLUID;

AMINO ACID BLOOD LEVEL; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; CROSSOVER PROCEDURE; DIALYSATE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; MEAL; METABOLISM; PERITONEAL DIALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; ULTRAFILTRATION;

EID: 0033376603     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: 10.1177/089686089901900504     Document Type: Article

References (40)

1. The USRDS Dialysis Morbidity and Mortality Study: Wave 2. United States Renal Data System. Am J Kidney Dis 1997; 30(2 Suppl 1):67-85.
2. Lindholm B, Wang T, Heimbürger O, Bergström J. Influence of different treatments and schedules on the factors conditioning the nutritional status in dialysis patients. Nephrol Dial Transplant 1998; 13(Suppl 6):66-73.
3. Culleton B, Parfrey PS. Cardiovascular risk in continuous ambulatory peritoneal dialysis patients. Perit Dial Int 1996; 16:10-12.
4. Dobbie JW. Morphology of the peritoneum in CAPD. Blood Purif 1989; 7:74-85.
5. Nakayama M, Kawaguchi Y, Yamada K, Hasegawa T, Takazoe K, Katoh N, et al. Immunohistochemical detection of advanced glycosylation end-products in the peritoneum and its possible pathophysiological role in CAPD. Kidney Int 1997; 51:182-6.
6. Grodstein GP, Blumenkrantz MJ, Kopple JD, Moran JK, Coburn JW. Glucose absorption during continuous ambulatory peritoneal dialysis. Kidney Int 1981; 19:564-7.
7. Lindholm B, Karlander SG. Glucose tolerance in patients undergoing continuous peritoneal dialysis. Acta Med Scand 1986; 220:477-83.
8. Mak RH, De Fronzo RA. Glucose and insulin metabolism in uremia. Nephron 1992; 61:377-82.
9. Kopple JD, Blumenkrantz MJ, Jones MR, Moran JK, Coburn JW. Plasma amino acid levels and amino acid losses during continuous ambulatory peritoneal dialysis. Am J Clin Nutr 1982; 36:395.
10. Lindholm B, Bergström J. Nutritional aspects on peritoneal dialysis. Kidney Int 1992; 38:165-71.
11. Young GA, Kopple JD, Lindholm B, Vonesh EF, De Vecchi A, Scalamogna A, et al. Nutritional assessment of continuous ambulatory peritoneal dialysis patients: an international study. Am J Kidney Dis 1991; 17:462-71.
12. Peritoneal Dialysis Study Group. Adequacy of dialysis and nutrition in continuous peritoneal dialysis: association with clinical outcomes. Canada-USA (CANUSA). J Am Soc Nephrol 1996; 7:198-207.
13. Qureshi AR, Alvestrand A, Danielsson A, Divino-Filho JC, Gutierrez A, Lindholm B, et al. Factors predicting malnutrition in hemodialysis patients: a cross-sectional study. Kidney Int 1998; 53:773-82.
14. May RC, Kelly RA, Mitch WE. Metabolic acidosis stimulates protein degradation in rat muscle by a glucocorticoid-dependent mechanism. J Clin Invest 1986; 77:614-21.
15. Greiber S, Mitch WE. Mechanisms for protein catabolism in uremia: metabolic acidosis and activation of proteolytic pathways. Miner Electrolyte Metab 1992; 18:233-6.
16. Feriani M. Bicarbonate-buffered CAPD solutions: from clinical trials to clinical practice. Perit Dial Int 1997; 17(Suppl 2):S51-5.
17. Topley N, Kaur D, Petersen MM, Jörres A, Passlick-Deetjen J, Coles GA, et al. Biocompatibility of bicarbonate buffered peritoneal dialysis fluids: influence on mesothelial cell and neutrophil function. Kidney Int 1996; 49:1447-56.
18. Plum J, Lordnejad MR, Grabensee B. Effect of alternative peritoneal dialysis solutions on cell viability, apoptosis/necrosis and cytokine expression in human monocytes. Kidney Int 1998; 54:224-35.
19. Randerson DH, Chapman GV, Farrell PC. Amino acid and dietary status in CAPD patients. In: Atkins RC, Farrell PC, Thomson NM, eds. Peritoneal dialysis. Edinburgh: Churchill-Livingstone, 1981:171-91.
20. Watson PE, Watson ID, Batt RD. Total body water volumes for adult males and females estimated from simple anthropometric measurements. Am J Clin Nutr 1980; 33:27-39.
21. Twardowski ZJ. Clinical value of standardized equilibration tests in CAPD patients. Blood Purif 1989; 7:95-108.
22. Feriani M, Biasioli S, Borin D, Brendolan A, Gargantini L, Chiaramonte S, et al. Bicarbonate solutions for peritoneal dialysis: a reality. Int J Artif Organs 1985; 8:57-8.
23. Armstrong VW, Striebel JP, Thalacher F. Einfluss der Dauerperitonealdialyse (CAPD) auf die Plasmaaminosäurekonzentration von Patienten mit chronischer Niereninsuffizienz. Nieren-Hochdruckkrankheiten 1979; 5:198-201.
24. Bruno M, Bagnis C, Marangella M, Rovera L, Cantaluppi A, Linari F. CAPD with an amino acid dialysis solution: a long term cross over study. Kidney Int 1989; 35:1189-94.
25. Young GA, Dibble JB, Hobson SM, Tompkins L, Gibson J, Turney JH, et al. The use of an amino acid-based CAPD fluid over 12 weeks. Nephrol Dial Transplant 1989; 4:285-92.
26. Qamar IU, Levin L, Balfe JW, Balfe JA, Secker D, Zlotkin S. Effects of 3-month amino acid dialysis compared to dextrose dialysis in children on continuous ambulatory peritoneal dialysis. Perit Dial Int 1994; 14:34-41.
27. Kopple JD, Bernard D, Messana J, Swartz R, Bergström J, Lindholm B, et al. Treatment of malnourished CAPD patients with an amino acid based dialysate. Kidney Int 1995; 47:1148-57.
28. Faller B, Aparicio M, Faict D, De Vos C, de Precigout V, Larroumet N, et al. Clinical evaluation of an optimized 1.1% amino-acid solution for peritoneal dialysis. Nephrol Dial Transplant 1995; 10:1432-7.
29. Misra M, Ashworth J, Reaveley DA, Muller B, Brown EA, Seed M. Six-month prospective cross-over study to determine the effects of 1.1% amino acid dialysate on lipid metabolism in patients on continuous ambulatory peritoneal dialysis. Perit Dial Int 1997; 17:279-86.
30. Wahren J, Felig P, Hagenfeldt L. Effect of protein ingestion on splanchnic and leg metabolism in normal men and in patients with diabetes mellitus. J Clin Invest 1976; 57:987-99.
31. Arfeen S, Goodship TH, Kirkwood A, Channon S, Ward MK. 1% amino acid peritoneal dialysate: single cycle study in diabetic patients with end-stage renal disease. Am J Kidney Dis 1994; 23:86-90.
32. Goodship TH, Lloyd S, McKenzie PW, Earnshaw M, Smeaton I, Bartlett K, et al. Short term studies on the use of amino acids as an osmotic agent in continuous ambulatory peritoneal dialysis. Clin Sci 1987; 73:471-8.
33. Buse MG, Reid SS. Leucine: a possible regulator of protein turnover in muscle. J Clin Invest 1975; 56:1250-61.
34. Harty JC, Boulton H, Curwell J, Heelis N, Uttley L, Venning MC, et al. The normalized protein catabolic rate is a flawed marker of nutrition in CAPD patients. Kidney Int 1994; 45:103-9.
35. Feriani M, Carobi C, La Greca G, Buoncristiani U, Passlick-Deetjen J. Clinical experience with a 39 mmol/L bicarbonate-buffered peritoneal dialysis solution. Perit Dial Int 1997; 17:17-21.
36. Park MS, Heimbürger O, Bergström J, Waniewski J, Werynski A, Lindholm B. Peritoneal transport during dialysis with amino acid-based solutions. Perit Dial Int 1993; 13:280-8.
37. Passlick-Deetjen J, Koch R, Grabensee B. High osmolar amino acid solution: an alternative to glucose? Contrib Nephrol 1991; 89:134-46.
38. Yalow RS, Baumann WA. Plasma insulin in health and disease. In: Ellenberg M, Rifkin H, eds. Diabetes mellitus. New York: Medical Examination Publishing Inc., Excerpta Medica, 1983:119.
39. Sherwin RS, Basil C, Finkelstein FO, Fisher M, Black H, Hendler R, et al. Influence of uremia and hemodialysis on the turnover and metabolic effects of glucagon. J Clin Invest 1976; 57:722-31.
40. Plum J, Fusshöller A, Schoenicke G, Busch T, Erren C, Fieseler C, et al. In vivo and in vitro effects of an amino acid based and bicarbonate buffered peritoneal dialysis solutions with regard to peritoneal transport and cytokines/prostanoids dialysate concentrations. Nephrol Dial Transplant 1997; 12:1652-60.